ASH 2014: Intergroup trial C10403 shows that paediatric treatment regimens for acute lymphoblastic leukaemia improves overall and event-free survival in adolescents and young adults

At a press conference during the 2014 American Society of Hematology (ASH) Annual Meeting, Prof Wendy Stock (University of Chicago Medical Center, Chicago, IL) discusses the intergroup trial C10403, which showed that adolescent and young adult patients (1639 years old) with acute lymphoblastic leukaemia (ALL) had better overall and event-free survival with paediatric regimens compared to historical controls.